Managing the risks of immunosuppression

Current Opinion in Neurology

Volumn 24, Issue 3, 2011, Pages 217-223

  Riminton, D Sean ^a   Hartung, Hans Peter ^b   Reddel, Stephen W ^a  

^a ANZAC Research Institute   (Australia)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

adverse drug reactions; biological therapies; corticosteroids; demyelinating diseases; immunosuppression; neuroimmunology; quality improvement; risk management

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; FINGOLIMOD; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; NATALIZUMAB; RITUXIMAB;

AUTOIMMUNITY; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CYTOMEGALOVIRUS INFECTION; HEPATITIS B; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; JC VIRUS; METABOLIC DISORDER; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOSIS; NONHUMAN; PNEUMOCYSTOSIS; PREVENTIVE MEDICINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYOGENIC BACTERIUM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SIDE EFFECT; TUBERCULOSIS; VACCINATION; VIRUS REACTIVATION;

CARDIOVASCULAR DISEASES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; INFECTION; NEOPLASMS; RISK MANAGEMENT;

EID: 79955579207     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328346d47d     Document Type: Review

References (42)

1. Smith R. Communicating risk: the main work of doctors. Br Med J 2003; 327:691-692.
2. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361:1081-1087.
3. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-446.
4. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. (Pubitemid 47017468)
5. Vajdic CM, Mao L, van Leeuwen MT, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010; 116:1228-1234.
6. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823-2871.
7. Van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010; 340:c570.
8. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616-5623.
9. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111:1816-1819. (Pubitemid 351451487)
10. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605-611.
11. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-415.
12. Aktas O, Kü ry P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010; 6:373-382.
13. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362:416-426.
14. Tan CS, Koralnik I. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet 2010; 9:425-437.
15. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients. a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
16. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Rev Med 2010; 61:35-47.
17. Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75:1326-1332.
18. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8:28-31.
19. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy. What are the causal factors and can it be avoided? Arch Neurol 2010; 67:923-930.
20. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 2011; 231:73-77.
21. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68:295-303.
22. Tyler KL. Progressive multifocal leukoencephalopathy-can we reduce the risk in patients receving biological immunomodulatory therapies? Ann Neurol 2010; 68:271-274.
23. Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007; 8:58.
24. Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49:1815-1827.
25. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57 (RR-5):1-30; quiz CE2-CE4.
26. Sumelahti ML, Hakama M, Elovaara I, Pukkala E. Causes of death among patients with multiple sclerosis. Mult Scler 2010; 16:1437-1442.
27. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70:8-14.
28. Young JB, Neumayer HH, Gordon RD. Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk. Kidney Int 2010; 78 (Suppl. 118): S1-S7.
29. Hirst C, Swingler R, Compston DA, et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008; 79:1016-1021.
30. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764-770.
31. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560-1567. (Pubitemid 350205441)
32. Mackay IR, Leskovsek NV, Rose NR. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010; 35:199-205.
33. Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9:188-193.
34. Lysandropoulos AP, Du Pasquier RA. Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol 2010; 23:226-233.
35. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363-1365. (Pubitemid 39120128)
36. Stubgen JP. Tumour necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008; 37:281-292.
37. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9:409-411. (Pubitemid 40123592)
38. Clatworthy MR, Wallin EF, Jayne DR. Antiglomerular basement membrane disease after alemtuzumab. N Engl J Med 2008; 359:768-769.
39. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23:693-702.
40. Martin-Blondel G, Delobel P, Blancher A, et al. Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system infected with HIV. Brain 2011; 134:928-946.
41. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010; 5:504-510.
42. Davies RR, Russo MJ, Hong KN, et al. Increased short-and long-termmortality at low-volume Pediatric Heart Transplant Centers: should minimum standards be set? Retrospective data analysis. Ann Surg 2010 [Epub ahead of print].